Zenshine Pharmaceuticals

Nanjing Zenshine Pharmaceuticals Co., Ltd., a China-based small molecule drug developer, has announced that the National Medical Products Administration (NMPA) has accepted its New Drug Application (NDA) for ZX-7101A, an anti-influenza treatment targeting uncomplicated influenza in adults. The NDA is supported by data from a multi-center, randomized, double-blinded, placebo-controlled Phase…